UK cost body backs pricey Gilead hepatitis pill for some patients
By Ben Hirschler LONDON (Reuters) – Gilead Sciences’ expensive new hepatitis C pill has been endorsed for use in certain patients by Britain’s healthcare cost-effectiveness watchdog, after the U.S. firm provided more information. The National Institute for Health and Care Excellence (NICE) had told Gilead in June to come back with more data to support the use of Sovaldi, a drug whose sky-high U.S. price of $1,000 (£599.4) per pill has sparked fierce debate over costly modern medicines. Carole Longson, director of the NICE Centre for Health Technology Evaluation, said on Friday it was now provisionally recommending Sovaldi, also known as sofosbuvir, as a cost-effective treatment for some people with chronic hepatitis C. Gilead welcomed the decision to endorse Sovaldi as part of a combination treatment regimen, which it said would potentially make the drug available for the majority of hepatitis C patients. The new drug is recommended for people chronically infected with certain strains, or genotypes, of the disease, which can cause liver cirrhosis and, in a small percentage of people, liver cancer.